Charles Geyer Jr./LinkedIn
Jan 19, 2025, 04:13
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
A recent paper by Charles Geyer Jr., Chief Scientific Officer of NSABP Foundation, was mentioned by Yakup Ergün, Medical Oncologist at Antalya City Hospital, on X:
“Survival with T-DM1 in Residual HER2-Positive Breast Cancer (KATHERINE)
mFU: 8.4 years
- 7y-iDFS – 80.8 vs 67.1%
- 7y-OS – 89.1 vs 84.4%.”
“Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer”
Authors: Charles Geyer Jr. et al.
More posts featuring Yakup Ergün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29